Dermatol. praxi. 2022;16(3):164-166 | DOI: 10.36290/der.2022.033

The Use of Topical JAK Inhibitors in Dermatology

MUDr. Petra Matalová, Ph.D., MUC. Karolína Šimková
Ústav farmakologie LF UP a FN Olomouc

The JAK/STAT signaling pathway is activated by a number of cytokines and growth factors. Drugs known as JAK inhibitors (JAKi) target cytokine signalization by either oral or topical administration. Topical application can minimize the risk of side effects observed with systemic application. The following article discusses different skin diseases in which local JAKi have positive therapeutic effect. Their use also reduces the risk of side effects of immunosuppressants and local corticosteroids.

Keywords: JAK/STAT signaling, topical JAK inhibitors, skin diseases, dermatology, ruxolitinib, tofacitinib, abrocitinib, baricitinib, delgocitinib, upadacitinib.

Accepted: October 11, 2022; Published: October 17, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Matalová P, Šimková K. The Use of Topical JAK Inhibitors in Dermatology. Dermatol. praxi. 2022;16(3):164-166. doi: 10.36290/der.2022.033.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Straková N. Regulace dráhy JAK/STAT v nádorových buněčných liniích. In: Linkos.cz [Internet]. [Cited 2022 Jan 27]. Available from: https://www.linkos.cz/lekar-a-multidisciplinarni-tym/kongresy/po-kongresu/databaze-tuzemskych-onkologickych-konferencnich-abstrakt/regulace-drahy-jak-stat-v-nadorovych-bunecnych-liniich.
    2. James WD. Contact dermatitis and drug eruptions. In: Sciencedirect.com [Internet]. [Cited 2022 Jan 27]. Available from: https://www.sciencedirect.com/topics/medicine-and-dentistry/janus-kinase-inhibitor.
    3. Fragoulis GE, Mclness IB, Siebert S. JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis. In: Academic.oup.com [Internet]. [Cited 2022 Jan 27]. Available from: https://academic.oup.com/rheumatology/article/58/Supplement_1/i43/5365419.
    4. www.sukl.cz [2022 Jan 27].
    5. Solimani F, Meier K, Goreschi K. EmergingTopical and Systemic JAK Inhibitors in Dermatology. In: Pubmed.gov [Internet]. [Cited 2022 Jan 27]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6901833.
    6. Dai Z, Chen J, Chang Y. Selectiveinhibitionof JAK3 signaling issufficient to reverse alopecia areata. In: Pubmed.gov [Internet]. [Cited 2022 Jan 27]. Available from:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8119218/.
    7. Ferreira SB, Ferreira RB, Scheinberg MA. Topical tofacitinib in treatment of alopecia areata. In: Pubmed.gov [Internet]. [Cited 2022 Jan 27]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7416648.
    8. Traidl S, Freimooser S, Werfel T. Janus kinase inhibitors for the therapy of a topic dermatitis. In: Pubmed.gov [Internet]. [Cited 2022 Jan 27]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8439108.
    9. Boch K, Langan EA, Kirdin K. Lichen planus.In: Pubmed.gov [Internet]. [Cited 2022 Jan 27]. Available from:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8591129.
    10. Ferreira SB, Ferreira RB, Neto ACN. Topical Tofacitinib: A Janus Kinase Inhibitor for theTreatment of Vitiligo in an Adolescent Patient. In: Pubmed.gov [Internet]. [Cited 2022 Jan 27]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488419.
    11. https://www.creativebiomart.net/resource/signal-pathway-jak-stat-signal-pathway-389.htm.

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.